JP2013518130A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518130A5 JP2013518130A5 JP2012551333A JP2012551333A JP2013518130A5 JP 2013518130 A5 JP2013518130 A5 JP 2013518130A5 JP 2012551333 A JP2012551333 A JP 2012551333A JP 2012551333 A JP2012551333 A JP 2012551333A JP 2013518130 A5 JP2013518130 A5 JP 2013518130A5
- Authority
- JP
- Japan
- Prior art keywords
- bendamustine
- long
- term storage
- containing composition
- aqueous liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims 23
- 229960002707 bendamustine Drugs 0.000 claims 23
- 239000007788 liquid Substances 0.000 claims 19
- 230000007774 longterm Effects 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 9
- 239000003963 antioxidant agent Substances 0.000 claims 8
- 230000003078 antioxidant effect Effects 0.000 claims 8
- 235000006708 antioxidants Nutrition 0.000 claims 8
- 230000000087 stabilizing effect Effects 0.000 claims 6
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 229940035024 thioglycerol Drugs 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims 2
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims 2
- 235000019136 lipoic acid Nutrition 0.000 claims 2
- 229960002663 thioctic acid Drugs 0.000 claims 2
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- 150000007824 aliphatic compounds Chemical class 0.000 claims 1
- 150000001491 aromatic compounds Chemical class 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 229960002433 cysteine Drugs 0.000 claims 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 229960004452 methionine Drugs 0.000 claims 1
- 235000006109 methionine Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000473 propyl gallate Substances 0.000 claims 1
- 229940075579 propyl gallate Drugs 0.000 claims 1
- 235000010388 propyl gallate Nutrition 0.000 claims 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29910010P | 2010-01-28 | 2010-01-28 | |
| US61/299,100 | 2010-01-28 | ||
| PCT/US2011/022958 WO2011094565A1 (en) | 2010-01-28 | 2011-01-28 | Formulations of bendamustine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015160351A Division JP6133943B2 (ja) | 2010-01-28 | 2015-08-17 | ベンダムスチンの製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013518130A JP2013518130A (ja) | 2013-05-20 |
| JP2013518130A5 true JP2013518130A5 (enExample) | 2014-03-13 |
| JP5795600B2 JP5795600B2 (ja) | 2015-10-14 |
Family
ID=44309429
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012551333A Active JP5795600B2 (ja) | 2010-01-28 | 2011-01-28 | ベンダムスチンの製剤 |
| JP2015160351A Active JP6133943B2 (ja) | 2010-01-28 | 2015-08-17 | ベンダムスチンの製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015160351A Active JP6133943B2 (ja) | 2010-01-28 | 2015-08-17 | ベンダムスチンの製剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (17) | US8609707B2 (enExample) |
| EP (3) | EP3158991B1 (enExample) |
| JP (2) | JP5795600B2 (enExample) |
| CA (1) | CA2787568C (enExample) |
| CY (2) | CY1118769T1 (enExample) |
| DK (2) | DK2528602T4 (enExample) |
| ES (2) | ES2609106T5 (enExample) |
| HR (2) | HRP20161771T4 (enExample) |
| HU (2) | HUE054836T2 (enExample) |
| LT (2) | LT2528602T (enExample) |
| PL (2) | PL3158991T3 (enExample) |
| PT (2) | PT3158991T (enExample) |
| RS (2) | RS62327B1 (enExample) |
| SI (2) | SI2528602T2 (enExample) |
| SM (3) | SMT202100348T1 (enExample) |
| WO (1) | WO2011094565A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3158991B1 (en) | 2010-01-28 | 2021-03-17 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| US20120237492A1 (en) | 2011-02-18 | 2012-09-20 | Kythera Biopharmaceuticals, Inc. | Treatment of submental fat |
| WO2013112762A1 (en) * | 2012-01-24 | 2013-08-01 | Innopharma, Inc. | Bendamustine compositions and methods therefore |
| WO2013123227A1 (en) * | 2012-02-14 | 2013-08-22 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| ES2718902T3 (es) * | 2012-03-20 | 2019-07-05 | Eagle Pharmaceuticals Inc | Composición líquida destinada a ser utilizada en un método de tratamiento de condiciones en respuesta a la bendamustina en pacientes que requieren volúmenes reducidos para administración |
| HUE064884T2 (hu) * | 2012-03-20 | 2024-04-28 | Eagle Pharmaceuticals Inc | Bendamusztin kiszerelések |
| CN109953954A (zh) | 2013-08-27 | 2019-07-02 | V·沃道里斯 | 苯达莫司汀医药组合物 |
| TW201518291A (zh) * | 2013-09-20 | 2015-05-16 | 參天製藥股份有限公司 | 含聚乙二醇之組成物 |
| US20160235717A1 (en) * | 2013-10-11 | 2016-08-18 | Luitpold Pharmaceuticals, Inc. | Bendamustine pharmaceutical compositions |
| US9320730B2 (en) | 2014-03-13 | 2016-04-26 | Vasilios Voudouris | Bendamustine solid dispersions and continuous infusion |
| WO2016005995A2 (en) * | 2014-07-10 | 2016-01-14 | Leiutis Pharmaceuticals Pvt. Ltd. | Glycol free stable liquid compositions of bendamustine |
| US9603930B2 (en) | 2014-12-04 | 2017-03-28 | Navinta, Llc | Liquid bendamustine formulation |
| KR20180100309A (ko) * | 2015-11-04 | 2018-09-10 | 키쎄라 바이오파마슈티컬즈 인코포레이티드 | 데옥시콜산 및 이의 염을 사용한 축적된 지방의 치료 방법 |
| US11826466B2 (en) | 2016-08-31 | 2023-11-28 | Navinta, Llc | Bendamustine solution formulations |
| US10905677B2 (en) | 2016-08-31 | 2021-02-02 | Navinta, Llc | Bendamustine solution formulations |
| EP3773498B1 (en) | 2018-03-29 | 2022-06-22 | Project Pharmaceutics GmbH | Liquid pharmaceutical formulation |
| CA3108321A1 (en) | 2018-08-17 | 2020-02-20 | Hospira Australia Pty Ltd | Liquid bendamustine pharmaceutical compositions |
| US11730815B2 (en) | 2018-11-26 | 2023-08-22 | Good Health, Llc | Stable liquid pharmaceutical compositions comprising bendamustine |
| JP2020090481A (ja) * | 2018-11-27 | 2020-06-11 | 日本化薬株式会社 | ベンダムスチンを含有する溶液製剤 |
| JP7235288B2 (ja) * | 2019-01-07 | 2023-03-08 | コーアイセイ株式会社 | ベンダムスチンの液体製剤 |
| WO2020170104A1 (en) * | 2019-02-18 | 2020-08-27 | Shilpa Medicare Limited | Liquid bendamustine parenteral compositions |
| JPWO2021161876A1 (enExample) * | 2020-02-10 | 2021-08-19 | ||
| EP4134068A4 (en) * | 2020-04-09 | 2024-02-07 | Bika Biotechnology (Guangzhou) Co., Ltd. | Bendamustine composition and use thereof |
| CA3235585A1 (en) | 2021-10-22 | 2023-04-27 | Andreas Schutz | Liquid pharmaceutical formulation |
| GB202118175D0 (en) | 2021-12-15 | 2022-01-26 | Arecor Ltd | Novel composition |
| US11707450B1 (en) | 2022-03-03 | 2023-07-25 | Slayback Pharma Llc | Stable pharmaceutical compositions of bendamustine |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE159289C (enExample) | 1903-10-08 | 1905-03-16 | ||
| DE80967C (enExample) | ||||
| DE152989C (enExample) | ||||
| US4071620A (en) | 1977-01-10 | 1978-01-31 | American Home Products Corporation | Stabilization of oxygen sensitive dose forms |
| DD152989A1 (de) | 1980-09-11 | 1981-12-16 | Klaus Kunze | Anordnung zur korrektur von soll-und istwerten |
| DD159289A1 (de) * | 1981-06-01 | 1983-03-02 | Uwe Olthoff | Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen |
| DE3446873A1 (de) * | 1984-12-21 | 1986-07-10 | Merckle Gmbh | Fluessige diclofenac-zubereitungen |
| US5204335A (en) | 1986-10-31 | 1993-04-20 | Asta Pharma Aktiengesellschaft | Ifosfamide lyophilisate and process for its preparation |
| US4879286A (en) | 1987-01-28 | 1989-11-07 | Lyphomed, Inc. | Cyclophosphamide |
| US5223515A (en) | 1988-08-18 | 1993-06-29 | Takeda Chemical Industries, Ltd. | Injectable solution containing a pyridyl methylsulfinylbenzimidazole |
| ATE187071T1 (de) | 1993-10-27 | 1999-12-15 | Upjohn Co | Stabilisiertes prostaglandin e1 |
| CA2181241C (en) | 1994-01-24 | 2000-04-25 | Dadi Jamshed Dhabhar | Process for solubilizing difficultly soluble pharmaceutical actives |
| US6261537B1 (en) | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
| EP1019034A2 (en) | 1997-07-01 | 2000-07-19 | Atherogenics, Inc. | Antioxidant enhancement of therapy for hyperproliferative conditions |
| WO1999053918A1 (en) * | 1998-04-20 | 1999-10-28 | Eisai Co., Ltd. | Stabilized compositions containing benzimidazole-type compounds |
| US6569402B1 (en) | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| US6686365B2 (en) * | 2000-02-04 | 2004-02-03 | Eli Lilly And Company | Pharmaceutical composition |
| US6989139B2 (en) | 2000-02-15 | 2006-01-24 | Bristol-Myers Squibb Pharma Company | Matrix metalloproteinase inhibitors |
| WO2001097861A2 (en) | 2000-06-21 | 2001-12-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| CA2413957A1 (en) | 2000-06-21 | 2001-12-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
| EP1311302A2 (en) | 2000-06-21 | 2003-05-21 | Bristol-Myers Squibb Pharma Company | Pharmaceuticals for the imaging of angiogenic disorders |
| AUPQ849900A0 (en) | 2000-06-30 | 2000-07-27 | Dbl Australia Pty Ltd. | Injectable composition |
| EP1311301A2 (en) | 2000-07-06 | 2003-05-21 | Bristol-Myers Squibb Pharma Company | Stable radiopharmaceutical compositions and methods for preparation thereof |
| WO2002032427A1 (en) * | 2000-10-20 | 2002-04-25 | Galephar M/F | Stable oral formulation containing benzimidazole derivative |
| US7252799B2 (en) * | 2001-08-31 | 2007-08-07 | Clearant, Inc. | Methods for sterilizing preparations containing albumin |
| CA2493878C (en) * | 2002-07-30 | 2013-07-23 | Wyeth | Parenteral formulations containing a rapamycin hydroxyester |
| US20060035945A1 (en) | 2003-05-30 | 2006-02-16 | Giorgio Attardo | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases |
| US20060001597A1 (en) | 2004-06-30 | 2006-01-05 | Sokbom Han | Image processing apparatus, systems and associated methods |
| MX2007005361A (es) | 2004-11-05 | 2008-01-11 | Cephalon Inc | Tratamientos para cancer. |
| JP2008520652A (ja) | 2004-11-22 | 2008-06-19 | ヴィーナス・レメディーズ・リミテッド | 非水性液状の非経口的アセクロフェナク製剤 |
| US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| US7872050B2 (en) | 2005-03-14 | 2011-01-18 | Yaupon Therapeutics Inc. | Stabilized compositions of volatile alkylating agents and methods of using thereof |
| US20080200383A1 (en) | 2005-04-08 | 2008-08-21 | Amylin Pharmaceuticals, Inc. | Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| CN1850048A (zh) | 2006-06-09 | 2006-10-25 | 山东蓝金生物工程有限公司 | 一种含血管抑制剂的抗癌缓释注射剂 |
| EP2052723A4 (en) | 2006-08-14 | 2010-07-28 | Eisai R&D Man Co Ltd | STABLE LYOPHILIZED PREPARATION |
| JP5721949B2 (ja) | 2006-10-12 | 2015-05-20 | アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | 複合薬剤 |
| US8414909B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| DE102007003184A1 (de) | 2007-01-22 | 2008-07-24 | Orlowski, Michael, Dr. | Verfahren zur Beladung von strukturierten Oberflächen |
| US20090082416A1 (en) | 2007-09-25 | 2009-03-26 | Protia, Llc | Deuterium-enriched bendamustine |
| AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
| WO2010036702A1 (en) | 2008-09-25 | 2010-04-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
| AU2010204765A1 (en) | 2009-01-15 | 2011-07-28 | Cephalon, Inc. | Novel forms of bendamustine free base |
| RU2734236C2 (ru) | 2009-02-25 | 2020-10-13 | Софткемо Фарма Корп. | Композиции бендамустина и циклополисахарида |
| WO2010114770A1 (en) | 2009-03-30 | 2010-10-07 | Cerulean Pharma Inc. | Polymer-agent conjugates, particles, compositions, and related methods of use |
| US20100273730A1 (en) | 2009-04-27 | 2010-10-28 | Innopharmax, Inc. | Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof |
| JP2012525387A (ja) * | 2009-04-28 | 2012-10-22 | セファロン、インク． | ベンダムスチンの経口製剤 |
| CN101584668A (zh) | 2009-06-19 | 2009-11-25 | 江苏奥赛康药业有限公司 | 盐酸苯达莫司汀冻干粉针剂 |
| WO2010148288A2 (en) | 2009-06-19 | 2010-12-23 | Lyotropic Therapeutics, Inc. | Pharmaceutical formulations with low aqueous levels of free unbound drug |
| US20110015245A1 (en) | 2009-07-20 | 2011-01-20 | Valery Alakhov | Bendamustine amphiphilic cationic compositions |
| US8389558B2 (en) | 2009-07-20 | 2013-03-05 | Supratek Pharma Inc. | Bendamustine amphiphilic anionic compositions |
| US7772274B1 (en) * | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
| EP3158991B1 (en) | 2010-01-28 | 2021-03-17 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| WO2011103150A2 (en) | 2010-02-18 | 2011-08-25 | Cephalon, Inc. | Lyophilized preparations of bendamustine |
| EP2571357B1 (en) | 2010-05-21 | 2016-07-06 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| US9655898B2 (en) | 2010-07-28 | 2017-05-23 | Eagle Pharmaceuticals, Inc. | Pharmaceutical compositions containing pemetrexed having extended storage stability |
| WO2012059935A1 (en) | 2010-11-01 | 2012-05-10 | Shilpa Medicare Limited | Process for preparing bendamus tine hydrochloride monohydrate |
| JP2014516075A (ja) | 2011-06-06 | 2014-07-07 | シェブロン フィリップス ケミカル カンパニー エルピー | 癌治療のためのメタロセン化合物の使用 |
| JP6148250B2 (ja) | 2011-12-05 | 2017-06-14 | バイオ−ラッド ラボラトリーズ，インコーポレイティド | 組換え脱アミド化グリアジン抗原 |
| CA2857721C (en) | 2011-12-05 | 2022-05-31 | X-Body, Inc. | Pdgf receptor beta binding polypeptides |
| WO2013112762A1 (en) | 2012-01-24 | 2013-08-01 | Innopharma, Inc. | Bendamustine compositions and methods therefore |
| WO2013123227A1 (en) | 2012-02-14 | 2013-08-22 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| HUE064884T2 (hu) | 2012-03-20 | 2024-04-28 | Eagle Pharmaceuticals Inc | Bendamusztin kiszerelések |
| ES2718902T3 (es) | 2012-03-20 | 2019-07-05 | Eagle Pharmaceuticals Inc | Composición líquida destinada a ser utilizada en un método de tratamiento de condiciones en respuesta a la bendamustina en pacientes que requieren volúmenes reducidos para administración |
| JP6331468B2 (ja) | 2014-02-27 | 2018-05-30 | 住友ベークライト株式会社 | 金属ラミネート用フィルム、ラミネート金属板および金属容器 |
| US11707450B1 (en) * | 2022-03-03 | 2023-07-25 | Slayback Pharma Llc | Stable pharmaceutical compositions of bendamustine |
-
2011
- 2011-01-28 EP EP16020363.4A patent/EP3158991B1/en active Active
- 2011-01-28 JP JP2012551333A patent/JP5795600B2/ja active Active
- 2011-01-28 DK DK11737745.7T patent/DK2528602T4/da active
- 2011-01-28 HU HUE16020363A patent/HUE054836T2/hu unknown
- 2011-01-28 EP EP21162804.5A patent/EP3895694A1/en active Pending
- 2011-01-28 US US13/016,473 patent/US8609707B2/en active Active
- 2011-01-28 WO PCT/US2011/022958 patent/WO2011094565A1/en not_active Ceased
- 2011-01-28 PT PT160203634T patent/PT3158991T/pt unknown
- 2011-01-28 PL PL16020363T patent/PL3158991T3/pl unknown
- 2011-01-28 HU HUE11737745A patent/HUE031208T2/hu unknown
- 2011-01-28 PT PT117377457T patent/PT2528602T/pt unknown
- 2011-01-28 SI SI201131066T patent/SI2528602T2/sl unknown
- 2011-01-28 EP EP11737745.7A patent/EP2528602B2/en active Active
- 2011-01-28 SM SM20210348T patent/SMT202100348T1/it unknown
- 2011-01-28 RS RS20210749A patent/RS62327B1/sr unknown
- 2011-01-28 SI SI201131979T patent/SI3158991T1/sl unknown
- 2011-01-28 CA CA2787568A patent/CA2787568C/en active Active
- 2011-01-28 ES ES11737745T patent/ES2609106T5/es active Active
- 2011-01-28 SM SM20170043T patent/SMT201700043T1/it unknown
- 2011-01-28 RS RS20161169A patent/RS55491B2/sr unknown
- 2011-01-28 HR HRP20161771TT patent/HRP20161771T4/hr unknown
- 2011-01-28 LT LTEP11737745.7T patent/LT2528602T/lt unknown
- 2011-01-28 ES ES16020363T patent/ES2875374T3/es active Active
- 2011-01-28 PL PL11737745T patent/PL2528602T5/pl unknown
- 2011-01-28 LT LTEP16020363.4T patent/LT3158991T/lt unknown
- 2011-01-28 DK DK16020363.4T patent/DK3158991T3/da active
-
2013
- 2013-09-19 US US14/031,879 patent/US9265831B2/en active Active
-
2015
- 2015-08-17 JP JP2015160351A patent/JP6133943B2/ja active Active
-
2016
- 2016-02-02 US US15/013,436 patent/US9572797B2/en active Active
- 2016-02-02 US US15/013,424 patent/US9572796B2/en active Active
- 2016-12-22 CY CY20161101334T patent/CY1118769T1/el unknown
-
2017
- 2017-01-20 SM SM201700043T patent/SMT201700043B/it unknown
- 2017-02-14 US US15/432,335 patent/US10010533B2/en active Active
-
2018
- 2018-06-22 US US16/015,656 patent/US20180296536A1/en not_active Abandoned
- 2018-06-22 US US16/015,580 patent/US20180296535A1/en not_active Abandoned
-
2019
- 2019-07-12 US US16/509,920 patent/US11103483B2/en active Active
-
2021
- 2021-06-09 HR HRP20210915TT patent/HRP20210915T1/hr unknown
- 2021-06-16 CY CY20211100540T patent/CY1124262T1/el unknown
- 2021-08-26 US US17/412,623 patent/US20210393594A1/en not_active Abandoned
-
2022
- 2022-12-14 US US18/081,251 patent/US11872214B2/en active Active
- 2022-12-14 US US18/081,238 patent/US11844783B2/en active Active
-
2023
- 2023-10-31 US US18/498,259 patent/US20240075013A1/en not_active Abandoned
-
2024
- 2024-04-25 US US18/646,329 patent/US12343333B2/en active Active
- 2024-04-25 US US18/646,171 patent/US12138248B2/en active Active
- 2024-10-09 US US18/910,904 patent/US20250177356A1/en active Pending
-
2025
- 2025-02-24 US US19/061,465 patent/US12350257B2/en active Active
- 2025-06-05 US US19/229,424 patent/US20250295637A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013518130A5 (enExample) | ||
| HRP20161771T4 (hr) | Formulacije bendamustina | |
| JP2015506989A5 (enExample) | ||
| ES2656901T3 (es) | Una formulación estabilizada de pemetrexed | |
| RU2016119746A (ru) | Стабильный состав инсулина глулизин | |
| WO2012015810A3 (en) | Pharmaceutical compositions containing pemetrexed having extended storage stability | |
| JP2010265321A5 (enExample) | ||
| JP2015527402A5 (enExample) | ||
| AR092470A1 (es) | Formulaciones acuosas estables de adalimumab | |
| BR112014009146A2 (pt) | formulações de etanercepte estabilizadas com aminoácidos | |
| CO6311066A2 (es) | Composiciones de alta densidad que contienen posaconazol y formulaciones que comprenden las mismas | |
| EA201290128A1 (ru) | Новые макроциклические ингибиторы репликации вируса гепатита с | |
| RU2019118696A (ru) | Фармацевтические композиции, содержащие инсулин | |
| JP2017514924A5 (enExample) | ||
| MX2017010945A (es) | Preparacion solida. | |
| MX2015015356A (es) | Formulacion estabilizada de pemetrexed. | |
| JP2015514120A5 (enExample) | ||
| ECSP12011699A (es) | Tableta | |
| EA201490175A1 (ru) | Составы дезоксихолевой кислоты и ее солей | |
| AR090592A1 (es) | Sales de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-feniletoxi)fenil]etil}amino)-1-hidroxietil]-8-hidroxiquinolin-2(1h)-ona | |
| EA201201239A1 (ru) | Композиция, содержащая в качестве активного ингредиента l-карнитин в комбинации с гидроксикинуренин-о-бета-dl-глюкозидом, для предотвращения и/или лечения патологий глаза, вызванных ультрафиолетовым излучением | |
| EA201170287A1 (ru) | Фармацевтические композиции и способы их стабилизации | |
| RU2019119405A (ru) | Лиофилизированные фармацевтические композиции далбаванцина | |
| MX2017016862A (es) | Composicion farmaceutica estable para administracion oral. | |
| EA201490363A1 (ru) | Новые составы на основе (триметоксифениламино)пиримидинилов |